• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Catalog Number TF-19A
Medical Device Problem Codes Device Stenosis (4066); Intravalvular regurgitation (4068)
Health Effect - Clinical Codes Aortic Valve Stenosis (1717); Dyspnea (1816); Aortic Valve Insufficiency/ Regurgitation (4450)
Date of Event 09/03/2024
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
As reported in a research article, first-in-human: leaflet laceration with balloon mediated annihilation to prevent coronary obstruction with radiofrequency needle (llamacorn) for valve-in-valve transcatheter aortic valve replacement.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device was received for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.D4: the udi number is not known as the lot number was not provided.Literature attachment: article titled "leaflet laceration with balloon mediated annihilation to prevent coronary obstruction with radiofrequency needle (llamacorn) for valve-in-valve transcatheter aortic valve replacement.
 
Event or Problem Description
The article, "first-in-human: leaflet laceration with balloon mediated annihilation to prevent coronary obstruction with radiofrequency needle (llamacorn) for valve-in-valve transcatheter aortic valve replacement" was reviewed.The article presented a case study of a 84 yrs old patient with new york heart association (nyha) iii dyspnea and chronic coronary syndromes (ccs) iii angina.It was reported that on an unknown date, a 19mm trifecta valve was implanted.It was then reported the patient presented severe aortic stenosis due to degenerated aortic valve bioprosthesis.Aortic stenosis (as), left ventricular ejection fraction (lvef) 58%, mavg 36 mmhg, dimensionless velocity index (dvi) 0.2, 2d, eoa0.5cm2; 3+ transvalvular ar.Cardiac computed tomography revealed left main coronary artery(lmca) height 8.8 mm, ventricular tachycardia (vtc) 38.8mm.A decision was made to perform a transcatheter valve-in-valve procedure with a 23mm navitor valve in degenerative 21 mm trifecta (abbott) aortic prosthesis.The procedures were performed under general anesthesia in the cardiac catheterization laboratory with fluoroscopic and transoesophageal echocardiogram (tee) guidance.Intravenous unfractionated heparin was administered to an activated clotting time of >300.To prevent coronary obstruction during transcatheter valve-in-valve procedure, the left coronary cusp of the trifecta valve was intentionally perforated with an 0.014" asahi astato wire, followed by sequential ballooning with a 4x20mm abbott trek balloon.Fluoroscopic and tee confirmed leaflet traversalaflet with a post dilation with a true 22 x 45 mm balloon (bd) for inside-out leaflet annihilation.30 day follow up-showed the patient had a successful uncomplicated tavr with no coronary obstruction and no conduction abnormalities necessitating permanent pacemaker implantation, discharged to home and were alive at 30-day follow-up.No patient suffered stroke or vascular complications.In conclusion, llamacorn represents a potential alternative as a modification of unicorn to facilitate the use of sev for valve in valve procedures.Further investigation of llamacorn appears warranted.[anthony c.Camuglia, mbbs, (hons1, monash), mha, (monash), fracp, fcsanz, department of cardiology, princess alexandra hospital, university of queensland, 199 ipswich rd, woolloongabba, brisbane qld 4102, australia.Email: anthony.Camuglia@health.Qld.Gov.Au].
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SJM TRIFECTA VALVE
Common Device Name
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL #3014918977
edificio #44 calle 0, ave. 2
el coyol alajuela 1897- 4050
CS   1897-4050
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key20352426
Report Number2135147-2024-04838
Device Sequence Number15453685
Product Code LWR
UDI-Device Identifier05414734052016
UDI-Public05414734052016
Combination Product (Y/N)N
Initial Reporter CountryAS
PMA/510(K) Number
P100029
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Literature
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 10/02/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Catalogue NumberTF-19A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 09/10/2024
Initial Report FDA Received Date10/02/2024
Was Device Evaluated by Manufacturer? (Y/N) No
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age84 YR
Patient SexFemale
-
-